Naoko Takebe to Ipilimumab
This is a "connection" page, showing publications Naoko Takebe has written about Ipilimumab.
Connection Strength
0.375
-
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers. J Immunother Cancer. 2025 Dec 21; 13(12).
Score: 0.244
-
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res. 2017 Jun 15; 23(12):2972-2980.
Score: 0.131